体部伽玛刀联合康莱特注射液治疗老年肺癌的疗效观察

目的：观察康莱特注射液联合体部伽玛刀治疗老年肺癌临床疗效。方法：采取随机对照分组，将100例经病理组织学确诊的老年NSCLC患者，临床分期Ⅲa-Ⅲb，分为两组，伽马刀组行体部伽马刀治疗，综合组给予体部伽马刀联合康莱特治疗。观察治疗后近期疗效、生活质量改善状况、骨髓抑制发生率及远期疗效。结果：综合组、伽玛刀组各50例，近期有效率分别为92％和80％。综合组Karnofsky评分改善者45例（90％），伽玛刀组改善者30例（60％），综合组优于伽玛刀组（P〈0．05）。综合组生活质量改善率92％（46／50）；伽玛刀组为76％（38／50），综合组优于伽玛刀组（P〈0．05）。两组治疗后第1、2周骨髓2度以上毒性发生率第2周时有显著性差异（P〈0．05）。综合组、伽玛刀组1年生存率分别为82．0％、76．0％，2年生存率分别为46．0％、40．0％；两组中位生存期分别为19．9个月、16．5个月。结论：康莱特注射液与体部伽玛刀联合治疗老年肺癌近期疗效、生存质量、远期疗效都明显优于单纯体部伽马刀治疗，且骨髓抑制反应低于后者。

The clinical effects of whole body gamma knife combined with Kanlaite injection on aged patients with non -small cell lung cancer

Objective： To evaluate the clinical effects of whole body gamma knife combined with Kanlalte injection treatment on aged patients with non - small - cell - lung cancer （NSLLC）. Methods：Total of 100 NSCLC patients with Ⅲa- Ⅲ b determined by pathological histology were divided into two groups. Patients in gamma knife group were treated with whole body gamma knife, and those in the combined group were treated by whole body gamma knife combined with Kanlaite injection. Results：The efficiency rate in the combined group and gamma knife group were 92% and 80%. Forty five cases were improved in Karnofsky score in the combined group and 30 cases were improved in the gamma Knife group. The combined group was better than the gamma Knife group （P 〈 0.05 ）. Life quality improved rates in the combined group were 92% （46/50） ,and in the gamma Knife group was 76% （38/50）. The combined group was superior to the gamma knife group （P 〈 0.05 ）. After treatment, the hematotoxicity reaction in both two groups have significant difference at second week （P 〈 0.05）. In the combined group and gamma knife group 1 - ,2 - year survival rates were 82.0 % , 7 6.0 % and 4 6.0 % , 4 0.0 % , respectively. The median survival time was 19.9 months and 16.5 month. Conclusion： Kanglaite injection combined with gamma knife is superior to simple body gamma knife in treatment of aged lung cancer patients, and bone marrow suppression rate was significant lower than the latter.